• CSR Summary
• NCT00589914
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2024-0060 : Using Synthetic Controls to Improve Randomised Controlled Trials for Rare Diseases
• 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
• 2023-5195 : Predictive modeling of adverse events and symptoms patterns in large scale clinical trials
• 2022-5062 : Heterogeneous treatment effects estimation with multi-source data: evidence from bipolar disorder and schizophrenia trials
• 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
• 2022-4854 : Combining data sources to identify effect moderation for personalized mental health treatment
• 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
• 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
• 2021-4667 : Estimation of Geographic and Demographic Variabilities Associated with Schizophrenia Age of Onset and Duration of Untreated Psychosis
• 2020-4521 : Causally interpretable meta-analysis with missing data: Generalizing evidence from bipolar disorder and schizophrenia trials to a target population
• 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
• 2019-3941 : Factors moderating estimates of antipsychotic efficacy in schizophrenia
• 2019-3936 : Unbiased Treatment Efficacy Detection Methods with Patient Centered Outcomes
• 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
• 2017-1966 : Psychosis break through antipsychotic maintenance medication: An individual participant data meta-analysis
• 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
• 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
• 2016-0766 : Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials
• 2016-0725 : Investigation of Racial and Ethnic Differences in Cardiometabolic Health of Patients with Schizophrenia/Schizoaffective Disorder
• 2015-0644 : Generalizing treatment effects for bipolar disorder and schizophrenia to the US population: Generalizability of network meta-analysis
• 2015-0592 : Detection of uninformative clinics during the trial of a new drug using statistical and machine learning techniques